SUSTAIN trial programme: difference between revisions
Diff·revision 8 → 9·05:27, 11 Dec 2024
Difference between revision 8 and revision 9 of SUSTAIN trial programme. 8 lines changed; the page grew by 475 bytes.
| Revision 8 — 01:57, 9 Nov 2024 LipidLedgerLou (talk) add category for the trial programme 3,694 bytes +34 | Revision 9 — 05:27, 11 Dec 2024 MoveRequestMio (talk) convert the endpoint list to a table for comparability 4,169 bytes +475 | ||
|---|---|---|---|
| 32 | A secondary finding attracted attention: an increase in diabetic retinopathy complications in the semaglutide arm, concentrated in participants with pre-existing retinopathy and rapid glycaemic improvement. Rapid glucose lowering is a recognised precipitant of transient retinopathy worsening by other means, so the finding is generally attributed to the magnitude and speed of improvement rather than to the drug directly — an attribution that is plausible rather than established.{{r|marso2016s}} | 32 | A secondary finding attracted attention: an increase in diabetic retinopathy complications in the semaglutide arm, concentrated in participants with pre-existing retinopathy and rapid glycaemic improvement. Rapid glucose lowering is a recognised precipitant of transient retinopathy worsening by other means, so the finding is generally attributed to the magnitude and speed of improvement rather than to the drug directly — an attribution that is plausible rather than established.{{r|marso2016s}} |
| 33 | 33 | ||
| + | 34 | The [[SELECT trial|SELECT]] trial subsequently addressed cardiovascular outcomes in a different population and with a dedicated superiority design.{{r|lincoff2023}} | |
| + | 35 | ||
| 34 | == References == | 36 | == References == |
| 35 | {{reflist}} | 37 | {{reflist}} |
| 36 | <ref name="sorli2017">Sorli C, Harashima SI, Tsoukas GM, et al. "Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in type 2 diabetes (SUSTAIN 1)." ''The Lancet Diabetes & Endocrinology'' 5(4):251–260 (2017). PMID 28110911.</ref> | 38 | <ref name="sorli2017">Sorli C, Harashima SI, Tsoukas GM, et al. "Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in type 2 diabetes (SUSTAIN 1)." ''The Lancet Diabetes & Endocrinology'' 5(4):251–260 (2017). PMID 28110911.</ref> |
| 37 | <ref name="marso2016s">Marso SP, Bain SC, Consoli A, et al. "Semaglutide and cardiovascular outcomes in patients with type 2 diabetes." ''New England Journal of Medicine'' 375(19):1834–1844 (2016). DOI:10.1056/NEJMoa1607141. PMID 27633186.</ref> | 39 | <ref name="marso2016s">Marso SP, Bain SC, Consoli A, et al. "Semaglutide and cardiovascular outcomes in patients with type 2 diabetes." ''New England Journal of Medicine'' 375(19):1834–1844 (2016). DOI:10.1056/NEJMoa1607141. PMID 27633186.</ref> |
| + | 40 | <ref name="lincoff2023">Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." ''New England Journal of Medicine'' 389(24):2221–2232 (2023). PMID 37952131.</ref> | |
| + | 41 | ||
| + | 42 | == See also == | |
| + | 43 | * [[Semaglutide]] | |
| + | 44 | * [[STEP trial programme]] | |
| + | 45 | * [[SELECT trial]] | |
| 38 | 46 | ||
| 39 | {{DEFAULTSORT:SUSTAIN trial programme}} | 47 | {{DEFAULTSORT:SUSTAIN trial programme}} |